HLA Health HourMedicaid & MedicareInsuranceMental HealthNutritionFind a ProviderHealth JobsProvider Corner
Healthcare Markets
UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.
Saturday, November 21, 2026
Edition
HELPMORNING BRIEFING
HLA Network News
HealthLink of America
HEALTHLINK OF AMERICA NEWS / RESOURCES
NORTH CAROLINA HEALTH PLANS
NC MedicaidMedicareBlue Cross NCHealthy BlueAmeriHealth Caritas NCCarolina Complete HealthUnitedHealthcare Community PlanWellCare of NCAlliance HealthTrillium Health ResourcesVaya PartnersAetnaHumanaCigna
All plans ›
ADVERTISEMENT
ADVERTISE WITH HLA NETWORK NEWS
Reach patients, families and providers in their city.
Health brands only. Banner, sidebar, section, directory, jobs and Morning Briefing placements.
GET THE MEDIA KIT
Providers & Industry · Atlanta

FDA approves first drug for rare genetic brain disorder

Infilbray targets type 3 Gaucher disease, a genetic condition that damages the nervous system and causes balance and memory problems.

The U.S. Food and Drug Administration has approved Infilbray (venglustat), the first drug to treat neurological symptoms of type 3 Gaucher disease, according to FOX 5 Atlanta. The drug is approved for patients weighing at least 15 kilograms, or about 33 pounds.

Type 3 Gaucher disease is a rare inherited condition where the body cannot break down fatty substances properly because of a faulty enzyme. These substances build up in organs, tissues, and the brain, causing serious health problems over time. Unlike type 1 Gaucher disease, type 3 affects the brain and nervous system, leading to difficulties with balance, coordination, speech, memory, and thinking that can worsen over time.

Infilbray works by reducing the buildup of harmful substances throughout the body and in the brain. According to the FDA, the drug's ability to reach the brain means it can address the root cause of neurological symptoms. The Acting FDA Commissioner said the approval brings an important new treatment option to patients and their healthcare providers.

What you can do: Remove 'affecting children' from headline—sources do not establish this as a pediatric disorder. The 15 kg weight threshold is a dosing parameter, not an age indicator.

Sources

Not medical advice. HLA Network News reports health news. Talk to your doctor or care team about your own care. In a crisis, call or text 988. In an emergency, call 911.
ADVERTISEMENT · SIDEBAR 300x250
Reach health readers here. Advertise with HLA